a b s t r a c t Systematic reviews of the prevalence of different types of Human Papillomavirus (HPV) across a broad range of disease grades from normal to cancer are essential to gain basic knowledge of how widespread infections with the different HPV types are, and to provide information on the possible carcinogenicity of different HPV types. For HPV types that infect human mucosa, of which 12 are established causes of cervical cancer, we present the results of a systematic review and meta-analysis of 47 HPV types in cervical samples across the entire range of cervical diagnoses from normal to cervical cancer, restricted to studies using a number of well characterized PCR assays.
Introduction
Human papillomaviruses (HPVs) are a large and diverse group of viruses with 174 completely characterized types, with new HPV types being continuously found (Bernard et al., 2010; Bottalico et al., 2011; Chen et al., 2007; Chouhy et al., 2010; Ekstrom et al., 2011; Ekstrom et al., 2010; Foulongne et al., 2012; Kohler et al., 2011; Li et al., 2012; Nobre et al., 2009; Vasiljevic et al., 2008; Vasiljevic et al., 2007) . There are five major HPV genera: Alphapapillomavirus, Betapapillomavirus, Gammapapillomavirus, Mu papillomavirus and Nu papillomavirus. HPVs infect epithelial cells in genital mucosa (alphapapillomaviruses only), oral mucosa or skin (representatives of all five genera). HPV types belonging to different genera have less than 60% similarity, based on the nucleotide sequence of the capsid protein L1. Different viral species within a genus share between 60 and 70% similarity. A novel HPV type has less than 90% similarity to any other HPV type (de Villiers et al., 2004) . Novel HPV types are given a number only after the whole genome has been cloned and deposited with the International HPV Reference Center (Bernard et al., 2010; de Villiers et al., 2004) , which was established in Heidelberg by Dr. Ethel-Michele deVilliers in 1985 and transferred to the Karolinska Institutet in 2012 (www.hpvcenter.se).
HPVs cause a wide range of diseases from benign lesions to invasive tumors (Duensing and Munger, 2004; Munoz et al., 2003) . In 2009, an International Agency for Research on Cancer (IARC) working group classified 12 mucosal HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) as carcinogenic to humans (Group 1) (Schiffman et al., 2009; IARC, 2012) for their association with cervical cancer, hereafter also referred to as high-risk (HR) HPV types. These 12 types cluster together in the same evolutionary branch or "high-risk clade" that includes Alphapapillomavirus species groups 5, 6, 7, 9 and 11. Eleven additional types in the high-risk clade were classified as possibly carcinogenic (Group 2B) based upon their phylogenetic relatedness to Group 1 types,with the exception of HPV68, which was upgraded to probably carcinogenic (Group 2A). Other mucosal HPV types in the Alphapapillomavirus genus e.g. HPV6 and 11, can cause benign genital condylomas (Bernard et al., 2010) .
The cutaneous HPV types are commonly found in several skin lesions such as benign skin warts (Pfister and Ter Schegget, 1997) , actinic keratoses (AKs), non-melanoma skin cancers (NMSCs) (Curado et al., 2008) and keratoacanthomas (KAs) (Asgari et al., 2008; Forslund et al., 2003a) . Cutaneous HPV types are also commonly detected on healthy skin (Forslund et al., 2004) .
NMSCs such as squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are two of the most prevalent cancers among Caucasian populations worldwide (Oberyszyn, 2008 radiation is a well-known risk factor (Alam and Ratner, 2001 ), but there may also be other risk factors (Boukamp, 2005; Reichrath, 2006) . The increased incidence of SCC in immunocompromised individuals has suggested that an infection may be involved (Berg and Otley, 2002; Boukamp, 2005; Grulich et al., 2007; Lindelof et al., 2000) , with HPV being the most commonly studied candidate infectious agent (Asgari et al., 2008; Forslund et al., 2007) . Skin samples from SCC, AK, seborrheic keratosis (SK), and BCC commonly contain multiple HPV types, but typically at very low viral loads (Ekstrom et al., 2010; Forslund et al., 2003a Forslund et al., , 2003b Kullander et al., 2008; Vasiljevic et al., 2007 Vasiljevic et al., , 2008 . Cutaneous HPV types have also been implicated in the etiology of squamouscell carcinoma of the conjunctiva (Ateenyi-Agaba et al., 2010) .
Because of the extreme diversity of HPV types, it is an enormous undertaking to obtain an exact epidemiologic definition of which individual HPV types are associated with which diseases. In the field of mucosal HPV types, the use of cross-sectional metaanalyses across different disease grades have long been key to describing HPV type-specific prevalences and establishing the causality of individual HPV types with cervical cancer (Guan et al., 2013; Schiffman et al., 2009) . Hence, in the present paper, we expanded a recently published meta-analysis that reported the prevalence of the 13 established or probably carcinogenic HPV types across the full spectrum of cervical diagnoses from normal cytology to cancer (Alam et al., 2003; Guan et al., 2013) to describe all other mucosal HPV types, many of which have been tested for in a smaller number of studies and samples than the most frequent high-risk types.
We reasoned that a systematic review of type-specific prevalences might be useful also for the cutaneous HPV types. However, the spectrum of pre-malignant lesions is less well understood in the skin than in the cervix. In addition, in the field of cutaneous HPV types, the variety in different types of samples and assays used meant that the simple pooling of prevalences from unmatched studies might be misleading. We therefore present a systematic review restricted to case-control studies that have investigated exposure to cutaneous HPV types in skin cancer cases and controls. Differences in types of sample and assays used would then be affecting both cases and controls in different studies, and could be adjusted for. Although this design is not bias-free, e.g. if assays have low specificity or non-informative types of samples have been tested, these biases will typically be conservative, biasing any association towards the null.
Results

Mucosal HPV types
Four hundred and twenty-three studies met eligibility criteria, including a total of 371,951 eligible women. HPV type-specific prevalence is presented for 47 mucosal HPV types across eight grades of cervical diagnosis in Table 1 . Overall HPV prevalence increased with increasing severity of cervical disease from 12.6% in normal cytology to 89.5% in ICC (Table 1) . HPV16 was by far the most frequently detected type in every grade. Among women with normal cytology, type-specific prevalence ranged from 0.4 to 2.6% for Group 1 (HR) types, from 0.1 to 1.1% for Group 2A/2B types and from o0.1 to 1.1% for Group 3 types.
All 13 HPV types classified as established or probably carcinogenic (Group 1/2A) by IARC were more commonly found among patients with ICC than among subjects with normal cytology (Table 1) . Indeed, the prevalence of HPV16, HPV18 and 45 were higher in ICC than in any other grade of cervical diagnosis. Other carcinogenic types, however, were more frequently detected in intermediate cervical diagnoses than in ICC. Particular examples included HPV51 detected in 9.4 and 8.1% of LSIL and CIN1 respectively compared to only 1% of ICC, HPV52 detected in 10.1, 14.1 and 9.6% of CIN1, 2 and 3 respectively, compared to 3.2% of ICC, and HPV31 detected in 10.0 and 10.8% of CIN2 and CIN3 respectively compared to 3.5% of ICC.
Some HPV types classified as probably or possibly carcinogenic (Group 2A/2B), namely HPV26, 67, 68, 69, 73 and 82, were also more common in ICC than in normal cytology. Other Group 2A/2B types, for example HPV53 and 66, were more common in normal cytology than ICC and were also found in a higher proportion of low-grade diagnoses (e.g. 8.4 and 7.7% of LSIL respectively) than ICC (0.5 and 0.3% respectively).
Among other HPV types, that were relatively uncommon in normal cytology and invasive cancer, many were commonly detected in intermediate diagnoses, in particular the alpha-9 types 61, 62, 84 and 89.
The addition of individual type-specific prevalences within each disease grade produced totals well above above 100% for all diagnoses known to be caused by HPV, highlighting the frequent presence of multiple HPV types within the same women. Indeed, in a subset-analysis of studies providing the necessary data breakdown, the prevalence of multiple infections ranged from 12% in ICC up to 39% in CIN2.
Cutaneous HPV types
The initial search identified 41200 studies. After scanning of titles and abstracts, 119 studies were retained. Detailed investigation of abstracts identified 18 studies assessing exposure to cutaneous HPV types among patients with skin cancers (SCC, BCC) or precursor lesions (AK). Three studies Masini et al., 2003; Struijk et al., 2003) were excluded because the populations were overlapping. Finally 15 studies were included in the analysis.
Among the included studies, nine used hospital-based casecontrol design (Andersson et al., 2008; Asgari et al., 2008; Forslund et al., 2007; Iannacone et al., 2012 Iannacone et al., , 2013 Stark et al., 1998; Steger et al., 1990; Struijk et al., 2006; Waterboer et al., 2008) , one study used hospital-based case-control design among organ transplant patients (OTR) (Proby et al., 2011) , four studies used a population based design to identify cases and controls (Andersson et al., 2012; Casabonne et al., 2007; Karagas et al., 2006; Termorshuizen et al., 2004) and two studies used a prospective follow-up study design (Plasmeijer et al., 2011; Andersson et al., 2012) .
Results comparing prevalence of cutaneous HPV types in cases and controls are shown in Table 2 . There have been few studies of cutaneous HPV types in the alpha genus.
For the beta genus, there have been a large number of studies of SCC using serology and/or detection of HPV DNA using various sample types. Upon combination of types at the species level, the prevalence of species Beta-1, Beta-2 and Beta-3 were each significantly elevated in SCC compared to controls, both using serology and DNA detection. At the individual type level, the prevalence of antibodies against HPV8 (Beta-1), HPV15, HPV17, HPV38 (Beta-2), HPV49 and HPV76 (Beta-3) were elevated in SCC in comparison to controls, but corresponding differences for DNA detection did not meet statistical significance. In contrast, the prevalence of DNA of HPV24 (Beta-1) was significantly higher in SCC than controls, but the corresponding difference in antibody prevalence did not meet statistical significance. Species Beta-4 was represented only by HPV92, for which DNA was significantly more prevalent in SCC than in controls (Table 1) .
Data on HPV types of genus Gamma, Mu and Nu were fewer than for beta-types, deriving only from serology studies, and showed no significant differences in seroprevalence between cases and controls at an individual HPV type level, even if OR estimates were of the same magnitude as those detected for the beta types. However, upon combination of HPV types in the Gamma-1 species, antibody prevalence was significantly elevated in SCC versus controls.
For AK, a SCC precursor, the detection of Beta-1 types was significantly higher in cases than controls, driven by a significant difference in the prevalence of HPV24 DNA, similar to that seen for SCC.
In striking contrast to SCC, none of the cutaneous HPVs appeared to be significantly elevated in BCC in comparison to controls, neither by serology nor DNA detection (Table 1) .
Discussion
Mucosal HPV types
The present systematic review is the first to comprehensively report the prevalence of the full range of mucosal HPV types across the complete spectrum of cervical disease. We relied upon a methodology already established in a previous review restricted to the 13 established or probable HR HPV types (Guan et al., 2012) . However, whereas the previous review compared type-specific prevalence among HR HPV-positive women only (with the specific aim to identify differences in the carcinogenic potential of HR HPV types), we present type-specific prevalences for 47 mucosal HPV types as a proportion of all tested women. This approach gives a picture of the frequency of genital infection by HPV types in the general female population (using women with normal cytology as a proxy), and provides an estimate of the absolute fraction of cervical abnormalities that are positive for different HPV types. Lastly, data can also be used to compare the prevalence of HPV types in various lesions with that in normal cytology, in a case: control type of analysis, to give an estimate of causality. HPV16 was shown to be by far the most common type in women with normal cytology (2.6%), suggesting a substantial advantage over all other mucosal HPV types in terms of transmissibility and/or persistence. Other HR HPV types were detected in 0.4 to 1.0% of women with normal cytology. However, women with normal cytology were also shown to be infected with a broad range of other mucosal HPV types, with HPV53 (1.1%), 62 (1.0%), 70 (0.8%) and 6 (0.8%) being the most common.
The major novelty of the current review was to reveal the broad range of non-HR HPV types that are commonly detected in low and high-grade cervical abnormalities, and the very high prevalence of multiple infections in these lesions. Such a high proportion of multiple infections has important implications for the estimation of the fraction of low and high-grade cervical abnormalities that are causally attributable to any one, or group, of HPV types.
Nevertheless, by simple addition of type-specific prevalences, the proportional impact of HPV-16/18 vaccination on cervical lesions can be predicted to rise from 17% of ASCUS, through 49% of HSIL, up to 70% of ICC. However, these estimates assume that all HPV-16 and -18 are causally related to the lesion in which they are found, even when another HPV type is present. This assumption may lead to an over-estimation of the proportional impact, particularly in low-and high-grade cervical abnormalities, where many multiple infections with a broad range of HPV types are involved. On the other hand, any cross-protection against other HPV types might increase the proportional impact.
In confirmation of their carcinogenic role, all HR HPV types were significantly more prevalent in ICC than in women with normal cytology. Importantly however, in contrast to HPV16, 18 and 45, other HR HPV types were detected in a larger proportion of intermediate diagnoses (e.g. HPV31, 52 and 58 each accounting 410% of CIN3) than in ICC, highlighting that the relative potential of HR types to cause low-and high-grade abnormalities is not the same as their relative potential to cause ICC. When comparing to prevalences in LSIL or in CIN3, the only 3 HPV types that were more common in ICC were HPV16, 18 and 45, emphasizing the fact the among the different HR types these 3 types constitute a group with particularly high ICC risks.
Lastly, a number of rare Group 2A/2B types, namely HPV26, 67, 68, 69, 73 and 82, were also more prevalent in ICC than normal cytology. These types may eventually be considered for addition to the list of Group 1-classified carcinogens and for becoming targets for cervical cancer prevention.
Cutaneous HPV types
The systematic review of case-control studies on cutaneous HPVs suggests that several HPV types in the Beta-1, Beta-2, Beta-3 and Beta-4 species are detected significantly more often in SCC than among controls, but that this is not the case for BCC. The genus Gamma is a large and continuously growing HPV genus with a plurality of HPV types that are each only rarely found. The studies on HPV gamma viruses are therefore fraught with low statistical power. However, the frequent finding of non-significant tendencies for increased risk does suggest that further studies on the presence of HPV types of the genus Gamma in SCC are warranted.
Interpretation of the data on cutaneous HPVs has a number of potential problems, including the limitation of the type-specific sensitivity and specificity of both serological and molecular assays and distinguishing findings of high viral load from findings of less than a viral copy per cell in skin cancer. At variance with the data on prevalence of mucosal HPV types in the cervix, the distinction of high-risk from low-risk cutaneous HPV types is in its infancy.
Materials and methods
Mucosal HPV types
Identification of studies Methods have been described previously (Guan et al., 2012) . Medline was used to search for publications from January 1990 to November 2011 using combinations of the MeSH terms: "cervical cancer," "cervical intraepithelial neoplasia," "HPV," "human," "female" and "polymerase chain reaction". References cited in retrieved articles were also evaluated. Eligible studies met the following criteria: (i) use of broad-spectrum consensus PCR assays based on the primers MY09/11, PGMY09/11, GP5+/6+, SPF10, SPF1/ GP6+ or L1C1/L1C2, and (ii) reporting of overall and type-specific HPV prevalence by strata of cytopathological and/or histopathological cervical diagnoses (see definitions below).
For each included study, the following data were extracted by cervical diagnosis: country, source of HPV DNA (cells versus biopsies/tissue), PCR primers, sample size and overall and typespecific prevalence of HPV DNA. If study methods suggested that additional relevant information was available (e.g., additional HPV types and/or more detailed stratification by cervical diagnosis), data requests were made to authors. For a subset of studies reporting such data, the overall prevalence of multiple infections was also extracted.
Cases were classified into eight grades of cervical diagnosis: those diagnosed by cytology as (i) normal; (ii) ASCUS; (iii) lowgrade squamous intraepithelial lesion (LSIL) or (iv) high-grade squamous intraepithelial lesion (HSIL); those diagnosed by histology as (v) CIN1; (vi) CIN2 or (vii) CIN3 (including squamous carcinoma in situ) and those diagnosed as (viii) ICC, which comprises both squamous cell carcinoma, adeno/adenosquamous carcinoma or cervical cancer of other/unspecified histology.
Statistical analysis
Overall HPV DNA prevalence is reported as a percentage of all women tested by consensus PCR, in descending order of their frequency of detection in ICC. Each HPV type was evaluated independently. Type-specific positivity was estimated only among those studies that both genotyped and reported the prevalence of the HPV type in question, and thus, denominators vary by type. Type-specific positivity includes that contributed by multiple HPV infections. The results have previously been published in more detail for the major 13 oncogenic HPV types (Guan et al., 2012) .
Cutaneous HPV types
Identification of studies
We searched PubMed for studies published up to 12th of May of 2013, using the search terms "Human papillomavirus" and "HPV" with the combination of "cutaneous" and "skin". All of the identified studies were cross-referenced to search for studies missed by the PubMed search.
Inclusion/exclusion criteria
All studies that provided analyses on exposures to cutaneous HPV types and risk of non-melanoma skin cancers, recorded separately for SCC of the skin, BCC or for AK, which is considered as a premalignant skin lesion. Studies that did not compare healthy and diseased individuals, merely reporting cutaneous HPV sequences and studies reporting case groups other than skin cancers were excluded, as well as review papers. If several studies reported on the same population, the study that was most recently published was chosen.
Data extraction
From the identified studies data was extracted on the number of diseased subjects and their healthy controls by cutaneous HPV type exposure status, by the laboratory method of exposure identification and by types of skin cancers.
Statistical analysis
We used the "meta" package from the statistical software R (www.r-project.org) to estimate summary effect estimates. Both fixed-and random-effects models were used and we weighed each study by the inverse variance method.
